The main shareholders implement a division of their shareholdings in Recipharm

B&E Participation AB owns 12,685,716 shares series A and 3,892,407 shares series
B in Recipharm, corresponding to approximately 46 percent of the capital and
about 86 percent of the votes. Backsell Eldered Holding AB owns all the shares
in B&E Participation AB. Lars Backsell and Thomas Eldered, founders of
Recipharm, each own 50 percent of the shares in Backsell Eldered Holding AB.
In the prospectus prepared in connection to the listing of Recipharm, dated 19
March 2014, it was announced that Lars Backsell and Thomas Eldered after the
listing had the intention to split their shareholdings in Recipharm, meaning
that B&E Participation AB transfers all shares held in Recipharm to companies
directly or indirectly owned by Lars Backsell and Thomas Eldered, individually.
In the prospectus it was further stated that Lars Backsell and Thomas Eldered
had committed not to sell or otherwise transfer their respective shareholdings
in Recipharm for a certain period after the first day of trading on NASDAQ OMX
Stockholm (lock-up period), whereby Lars Backsell undertook a lock-up period of
18 months and Thomas Eldered a period of 36 months.

Lars Backsell and Thomas Eldered have informed Recipharm that the split of
shareholdings described above will be carried out. Initially, B&E Participation
AB will distribute all shares in Recipharm which B&E Participation AB owns to
its owner Backsell Eldered Holding AB. Thereafter, a demerger of Backsell
Eldered Holding AB will be executed pursuant to Chapter 24 of the Swedish
Companies Act, whereby half of the shares series A will be distributed to a new
established limited liability company which by 100 percent will be owned by Lars
Backsell and the other half of the shares will be distributed to a new
established limited liability company which by 100 percent will be owned by
Thomas Eldered. The shares of series B in Recipharm, currently owned by B&E
Participation AB will, by the demerger of Backsell Eldered Holding AB, be
distributed in such a way that 3,858,690 shares will be transferred to the
company owned by Thomas Eldered and 33,717 shares to the company owned by Lars
Backsell. After the completion of the above-mentioned transactions, Lars
Backsell, through his wholly owned company, will own approximately 17 percent of
the capital and about 42 percent of the votes in Recipharm. Thomas Eldered,
through his wholly owned company, will own about 27 percent of the capital and
about 44 percent of the votes in Recipharm.

The Swedish Securities Council (AMN 2014:46) has granted Lars Backsell and
Thomas Eldered exemption from the takeover rules which, according to Chapter 3,
§ 1 Stock Market (Takeover Bids) Act (2006:451), otherwise would arise from the
division of shares in Recipharm AB as described above. The exemption also
includes the right for Lars Backsell and Thomas Eldered, respectively, to
acquire additional shares in Recipharm AB without triggering an obligation to
launch an offer to acquire the shares of Recipharm AB.

For further information, please contact:
Lars Backsell, Chairman of the Board, lars.backsell@recipharm.com, telephone:
+46 8 602 52 00
Thomas Eldered, CEO, Thomas.eldered@recipharm.com, telephone: +46 8 602 52 00

This information is published in accordance with the Swedish Securities Market
Act, the Swedish Financial Instruments Trading Act and/or the regulations of
NASDAQ OMX Stockholm. This information was submitted for publication on 17th
October 2014 at 14:00 CET.

About Recipharm
Recipharm is a leading CDMO (Contract Development and Manufacturing
Organisation) in the pharmaceutical industry based in Sweden employing some
1,750 employees. Recipharm offers manufacturing services of pharmaceuticals in
various dosage forms, production of clinical trial material including API and
pharmaceutical product development. Recipharm manufactures more than 250
different products to customers ranging from Big Pharma through to smaller
research- and development companies. Recipharm’s turnover is approximately SEK
2.6 billion and the Company operates development and manufacturing facilities in
Sweden, France, the UK, Germany, Spain and Italy and is headquartered in
Jordbro, Sweden. The Recipharm B-share (RECI B) is listed on Nasdaq OMX
Stockholm.

For more information on Recipharm and our services, please visit
www.recipharm.com.
Recipharm AB (publ)
Corporate identity number 556498-8425
Address Lagervägen 7, SE-136 50 Jordbro Telephone 46 8 602 52 00
Fax 46 8 81 87 03, www.recipharm.com